NEW YORK - Sunday, November 11th 2012 [ME NewsWire] Third Quarter Results Revenue from Continuing Operations of $222 million GAAP EPS from Continuing Operations of $0.35, includes $0.28 non-recurring tax benefit Non-GAAP EPS from Continuing Operations of $0.09 Announces Corporate Restructuring Concentrates resources on core business in North America and key European & Asian markets supported by increased marketing and sales Pursues sale of ChinaHR and evaluates options in developing markets Combined actions expected to reduce Operating Expense by approximately $130 million on an annualized basis Review of Strategic Alternatives Ongoing
...
Read more »
|
BOUDRY, Switzerland - Sunday, November 11th 2012 [ME NewsWire] (BUSINESS WIRE)-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. In the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study, a Celgene-sponsored, open-label, randomized, international study 861 metastatic pancreatic cancer patients were randomized to receive either ABRAXANE plus gemcitabine (125 mg/m2 followed by 1000 mg/m2 gemcitabine for 3 weeks followed by a week of rest) or gemcitabine alone (1000 mg/m2 administered
...
Read more »
|
ME Newswire / Business Wire INGELHEIM, Germany - Sunday, November 11th 2012 Pivotal Phase III interferon-free study being initiated following positive Phase IIb results For media outside of the U.S.A. , UK and Canada only Final results from the Phase IIb study, SOUND-C2, confirmed that up to 85 percent of hepatitis C (HCV) patients infected with the most prevalent type of HCV globally, genotype-1b (GT-1b), achieved and subsequently sustained viral cure with Boehringer Ingelheim’s interferon-free regimen, when measured 12 and 24 weeks (SVR12 & SVR24) after treatment. This high cure rate was achieved following just 28 weeks of treatment with the highly effective polymodal* therapy, faldaprevir (BI 201335)+, a potent next wave once daily protease inhibitor, and BI 207127+, a potent non-nucleoside polymerase inhibitor, plus ribavirin.1 These full results from the largest interferon-free trial of its kind to be concluded to date, include patients with
...
Read more »
|
HONG KONG - Saturday, November 10th 2012 [ME NewsWire] Record pre-tax income of US$204 million Record quarterly sales of US$8.7 billion Record market share of 15.6 percent Basic EPS of 1.58 US cents, or 12.25 HK cents Net cash reserves of US$3.6 billion (as of September 30, 2012) (BUSINESS WIRE)-- Lenovo Group today reported results for its second fiscal quarter ended September 30, 2012. Outgrowing the market in all geographies, Lenovo continued its push towards becoming the number one vendor in the PC industry, with record quarterly sales of $8.7 billion, an 11 percent increase year-over-year. While growing faster than the top four PC companies for three straight years, Lenovo also turned in another quarter of record pre-tax income at US$204 million, evidence that the Company continues to build upon its track record of profitable growth. During the second fis
...
Read more »
|
SAN ANTONIO - Friday, November 9th 2012 [ME NewsWire] (BUSINESS WIRE)-- Today, Kinetic Concepts, Inc. (KCI) announced that it has closed the sale of its Therapeutic Support Systems™ (TSS) business to Getinge AB (sto: GETIB) for a total deal value of $275 million. The TSS business, now owned by Getinge, includes a comprehensive portfolio of specialty therapeutic beds, mattress replacement systems, support surfaces and patient mobility devices for the therapeutic wound care, bariatric and critical care settings. To ensure that TSS customers continue to receive best-in-class service and commitment following the closing, KCI will continue to provide certain transition services to Getinge for a period of time. "Changing the clinical practice of medicine, a core competency that originated with the founding of the TSS business, is and will continue to be, fundamental to all we do at KCI," said Joe Woody, president & CEO, KCI, "As we close this corporate chapter and op
...
Read more »
|
|